Sponsor: 
GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Combination vaccines

Registered as a booster in people aged ≥4 years.

dTpa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine (reduced antigen formulation)

Each 0.5 mL monodose pre-filled syringe contains:

  • ≥2 IU diphtheria toxoid
  • ≥20 IU tetanus toxoid
  • 8 µg pertussis toxoid
  • 8 µg filamentous haemagglutinin
  • 2.5 µg pertactin
  • 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
  • 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
  • 32 D-antigen units inactivated poliovirus type 3 (Saukett)

Adsorbed onto 0.5 mg aluminium as aluminium hydroxide and aluminium phosphate.

Also contains traces of:

  • formaldehyde
  • polysorbate 80
  • polymyxin
  • neomycin

The product information and consumer medicine information for Boostrix-IPV have more details.

Audience: 
Infants and children
Previous

Boostrix

Next

Cervarix

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018

Definitions

dTpa
diphtheria-tetanus-acellular pertussis vaccine, reduced antigen content formulation
IPV
inactivated poliomyelitis vaccine
IU
international units